Numerous clinical trials, including DAPA-HF, EMPEROR-Preserved, CANVAS Program, DECLARE-TIMI, SOLOIST-WHF, SCORED, and CAMEO-DAPA, have investigated the effects of various SGLT2 inhibitors on cardiovascular outcomes and mortality in HF patients. This evidence concerns the gene SLC5A2 and hydrops fetalis.